13 November 2015
Researchers at the Translational Genomics Research Institute have discovered that a substance called propentofylline (PPF) could be a viable treatment for some types of brain cancer that currently have very low survival rates.
Initial tests have shown that PPF can have a positive effect on glioblastoma multiforme (GBM) by targeting the TROY protein. It also increases the effectiveness of both radiation and a common chemotherapy drug known as temozolomide for GBM patients.
GBM is particularly difficult treat due to the challenges of surgically removing the tumour without damaging healthy parts of the brain.
Catherine Ivy, founder and president of The Ben & Catherine Ivy Foundation (which partly funded the research), said: "GBM is one of the most aggressive of all cancers and it affects people of all ages. Funding research focused on helping patients survive longer is critical, and studies such as this advance our goal of not only improving treatments for brain cancer, but eventually finding a cure."
Posted by Edward Bartel
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.